Article
Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.
Laboratory investigation; a journal of technical methods and pathology - 1 Feb 2017
Hendrix Mary Jc, Kandela Irawati, Mazar Andrew P, Seftor Elisabeth A, Seftor Richard Eb, Margaryan Naira V, Strizzi Luigi, Murphy George F, Long Georgina V, Scolyer Richard A
Abstract excerpt
Metastatic melanoma is a highly aggressive skin cancer with a poor prognosis. It is the leading cause of skin cancer deaths with a median overall survival for advanced-stage metastatic disease of <6 months. Despite advances in the field with conventional and targeted therapies, the heterogeneity of melanoma poses the greatest ongoing challenge, ultimately leading to relapse and progression to a more...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.